Cargando…
Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma (MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2 activi...
Autores principales: | Ramakrishnan, Vijay, Kimlinger, Teresa, Haug, Jessica, Painuly, Utkarsh, Wellik, Linda, Halling, Timothy, Rajkumar, S. Vincent, Kumar, Shaji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503708/ https://www.ncbi.nlm.nih.gov/pubmed/23185517 http://dx.doi.org/10.1371/journal.pone.0050005 |
Ejemplares similares
-
Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014) -
Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2018) -
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016) -
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019) -
Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)